EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study

Margaux Louchet iD, Mathis Collier, Nathanaël Beeker, Laurent Mandelbrot iD, Jeanne Sibiude, Laurent Chouchana iD, Jean Marc Treluyer

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0295897 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Margaux Louchet und 6 weiteren Autor:innen. Beteiligte Einrichtung: UPR7323 "Pharmacology and Drug Evaluatioán in Children and Pregnant Women", Université Paris Cité, Paris, Île-de-France, France. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Anticonvulsants. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Describe the trends of exposure to harmful drugs during pregnancy over recent years in France.

Design

Nationwide cohort study.

Setting

The French National administrative health Data System (SNDS). Population Pregnancies starting between 2013 and 2019 and outcomes corresponding to live births, medical terminations of pregnancy, and stillbirths.

Methods

Each pregnancy was divided into a preconceptional period of 90 days before conception and three trimesters from conception to birth. Harmful drugs were defined according to their risks to the fetus: teratogenicity or fetotoxicity. Exposure was defined using the critical period during pregnancy for each type of harmful drug: preconceptional period or first trimester for teratogenic drugs and second or third trimesters for fetotoxic drugs. Main outcome measures Prevalence of pregnancies exposed to at least one harmful drug.

Results

Among 5,253,284 pregnancies, 204,402 (389 per 10,000) pregnancies were exposed to at least one harmful drug during the critical periods: 48,326 (92 per 10,000) pregnancies were exposed to teratogenic drugs during the preconceptional period or the first trimester, and 155,514 (299 per 10,000) pregnancies were exposed to fetotoxic drugs during the second or third trimesters. Teratogenic drugs were mainly retinoids for topical use (44 per 10,000 pregnancies), antiepileptics (13 per 10,000 pregnancies) and statins (13 per 10,000 pregnancies). Fetotoxic drugs were mainly non-steroidal anti-inflammatory drugs (NSAIDs), for systemic (128 per 10,000 pregnancies) and topical use (122 per 10,000 pregnancies). Exposure to teratogenic drugs decreased from the preconceptional period to the first trimester. Exposure to fetotoxic drugs decreased from the second to the third trimester. Between 2013 and 2019, we found a decrease in harmful drug exposure overall, mainly for topical and systemic NSAIDs and for topical retinoids.

Conclusions

In this nationwide study, about one in 25 pregnancies was exposed to at least one harmful drug, mainly NSAIDs and topical retinoids. Although the prevalence of harmful drug exposure decreased over the study period, NSAID exposure in the second and third trimester remains of concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalAnticonvulsantsFemalePregnancyHumansCohort StudiesFranceRetinoidsTeratogens

Substanzen

Anti-Inflammatory Agents, Non-SteroidalAnticonvulsantsRetinoidsTeratogens

Autor:innen und Institutionen

  • UPR7323 "Pharmacology and Drug Evaluatioán in Children and Pregnant Women", Université Paris Cité, Paris, Île-de-France, France.
  • Fédération Hospitalo-Universitaire PREMA, Université Paris Cité, Paris, Île-de-France, France.
  • Clinical Research Unit, Université de Paris CIC P1419, Assistance Publique-Hôpitaux de Paris, Paris, Île-de-France, France.
  • Department of Obstetrics and Gynecology, Louis Mourier Hospital, Assistance Publique-Hôpitaux de Paris, Paris, Île-de-France, France.
  • INSERM Infection, Antimicrobials, Modelling, Evolution U1137, Université Paris Cité, Paris, Île-de-France, France.
  • Department of Perinatal Pediatric and Adult Pharmacology, Regional Pharmacovigilance Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, Île-de-France, France.

ORCID-Profile: Margaux Louchet, Laurent Mandelbrot, Laurent Chouchana

Zitieren

APA

Louchet, M., Collier, M., Beeker, N., Mandelbrot, L., Sibiude, J., Chouchana, L., & Treluyer, J. M. (2024). Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0295897

Vancouver

Louchet M, Collier M, Beeker N, Mandelbrot L, Sibiude J, Chouchana L, et al. Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study. PLOS ONE. 2024. doi:10.1371/journal.pone.0295897

BibTeX
@article{Louchet2024,
  author = {Louchet, Margaux and Collier, Mathis and Beeker, Nathanaël and Mandelbrot, Laurent and Sibiude, Jeanne and Chouchana, Laurent and Treluyer, Jean Marc},
  title = {Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0295897}
}
Kostenlos starten →